CrystecPharma is pleased to announce that it has been named a finalist at the forthcoming CPHI Awards in Frankfurt.
The company’s entry, “Modified Supercritical-Antisolvent (mSAS®) particle engineering for stabilisation of biomolecules,” has been shortlisted in the Finished Formulation Award category. This award recognises excellence and innovation in technologies, products, processes, and services that contribute to the advancement of drug product formulation.
Being shortlisted for this prestigious award reflects CrystecPharma’s ongoing commitment to delivering innovative particle engineering solutions that enhance the stability and performance of pharmaceutical products.
If you would like to find out more about Crystec’s work in the area of biomolecule stabilisation, please book a meeting here.